Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Anglo American completes demerger of Valterra Platinum

(Sharecast News) - Anglo American has officially completed the demerger of its Valterra Platinum business following the approval of shareholders, allowing the company to focus on its copper, iron ore and crop nutrients operations. Valterra, which is valued at $11bn and already listed in Johannesburg, is scheduled to start trading in a secondary listing in London from Monday, with Anglo retaining a 19.9% interest in the platinum producer.

Anglo's chief executive Duncan Wanblad said the deal, which was part of significant restructuring plan announced last year, is a "major step in our plan to unlock the inherent value in our portfolio".

"Valterra Platinum has been a major part of the company for many years but now is the right time for it to optimise its value creation prospects on an independent path," he said.

Under the terms of the demerger, Anglo has to hold its 19.9% stake for at least 90 days, but said its interest will be "managed responsibly over time to effect a full separation".

The demerger officially took effect on 31 May following the approval by Anglo's shareholders on 30 April.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.